How International Standards for Molecular Biomarker Testing in Lung Cancer Have Influenced Which Tests are Routinely Performed

David L. Rimm, MD, PhD; Roy Herbst, MD, PhD

Video Categories: PMO Interview with the Innovator Series: Volume 12 and Video Library

Drs. Roy Herbst and David Rimm discuss the 50-gene panel that has become an ISLC-mandated standard for all patients with lung cancer; however, the components of cancer biomarker testing panels must be fluid and respond to new developments in the field as reported in the literature and/or at international cancer meetings, with adoption of the test predicated on standardization and the perceived value of the test.

April 14, 2015

CancerTREATMENT NGS+ in the Clinic

Description: Dr. Boccia describes cases in which he uses CancerTREATMENT NGS+ in his clinical practice.

October 1, 2014

Value of Specialty Pharmacy in Polycythemia Vera

Atheer Kaddis, SVP Sales/Business Development of Diplomat Specialty Pharmacy, describes in his opinion how specialty pharmacy can assist patients with polycythemia veraSupported through funding from Incyte